BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 11007827)

  • 21. Myeloperoxidase-antineutrophil cytoplasmic antibody causes different renal diseases by immune-complex formation and pauci-immune mechanism: A case report.
    Manabe S; Hatano M; Nakano M; Fujii T; Nitta K; Nagata M
    Pathol Int; 2017 Aug; 67(8):419-424. PubMed ID: 28580649
    [TBL] [Abstract][Full Text] [Related]  

  • 22. M2 macrophage infiltrates in the early stages of ANCA-associated pauci-immune necrotizing GN.
    Zhao L; David MZ; Hyjek E; Chang A; Meehan SM
    Clin J Am Soc Nephrol; 2015 Jan; 10(1):54-62. PubMed ID: 25516918
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical and pathologic characteristics of pauci-immune anti-myeloperoxidase antibody associated glomerulonephritis with nephrotic range proteinuria.
    Xu PC; Chen T; Gao S; Hu SY; Wei L; Yan TK
    Ren Fail; 2018 Nov; 40(1):554-560. PubMed ID: 30278797
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical presentation and outcome of pediatric ANCA-associated glomerulonephritis.
    Kouri AM; Andreoli SP
    Pediatr Nephrol; 2017 Mar; 32(3):449-455. PubMed ID: 27677979
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of Clinico-pathologic features and outcomes of ANCA negative and ANCA positive pauci immune crescentic glomerulonephritis: A single centre study.
    Gupta P; Bhargava V; Malik M; Gupta A; Bhalla AK; Gupta A; Tiwari V; Rana DS; Sapra RL
    Indian J Pathol Microbiol; 2024; 67(1):86-91. PubMed ID: 38358194
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical characteristics and outcome of pauci-immune glomerulonephritis in African Americans.
    Geetha D; Poulton CJ; Hu Y; Seo P; McGregor JA; Falk RJ; Hogan SL
    Semin Arthritis Rheum; 2014 Jun; 43(6):778-83. PubMed ID: 24387818
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Rapid-detection GBM-ANCA ELISA. An emergency tool for the early diagnosis of type I and II rapidly progressive glomerulonephritis].
    Arranz O; Ara J; Rodríguez R; Poveda R; Serra A; Solé-Amigó J; Fort J; Mirapeix E; Darnell A
    Nefrologia; 2001; 21(4):349-54. PubMed ID: 11816510
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Antineutrophil cytoplasmic antibodies (ANCA): clinico-pathologic correlations iin a series of 82 cases].
    Calvo Romero JM; Romero Requena J; Arévalo Lorido JC; Ramos Salado JL; Doblaré Castellano E; Vargas Pérez ML; Bureo Dacal P; Pérez Miranda M
    An Med Interna; 2002 Jan; 19(1):7-10. PubMed ID: 11989089
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Histopathological classification of pauci-immune glomerulonephritis and its impact on outcome.
    Naidu GS; Sharma A; Nada R; Kohli HS; Jha V; Gupta KL; Sakhuja V; Rathi M
    Rheumatol Int; 2014 Dec; 34(12):1721-7. PubMed ID: 24838685
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ANCA-negative pauci-immune renal vasculitis: histology and outcome.
    Eisenberger U; Fakhouri F; Vanhille P; Beaufils H; Mahr A; Guillevin L; Lesavre P; Noël LH
    Nephrol Dial Transplant; 2005 Jul; 20(7):1392-9. PubMed ID: 15855209
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Clinicopathologic Spectrum of Rapidly Progressive Glomerulonephritis Based on Glomerular Immune Deposition and Antineutrophil Cytoplasmic Antibody.
    Han F; Chen L; Le J; Choong P; Xu Y; Wang H; Chen J
    Appl Immunohistochem Mol Morphol; 2015; 23(10):704-10. PubMed ID: 26551339
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neutrophil degranulation in antineutrophil cytoplasmic antibody-negative pauci-immune crescentic glomerulonephritis.
    Wang F; Chen M; Zhao MH
    J Nephrol; 2009; 22(4):491-6. PubMed ID: 19662604
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Anti-neutrophil cytoplasmic antibodies (ANCA) in the glomerulonephritis].
    Kacprzyk F; Chrzanowski W
    Pol Arch Med Wewn; 1996 Jun; 95(6):514-23. PubMed ID: 9005420
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Idiopathic rapidly progressive glomerulonephritis and small vessel vasculitis].
    Zhou F; Zhang Y; Zhao M
    Zhonghua Nei Ke Za Zhi; 1997 Sep; 36(9):603-6. PubMed ID: 10436970
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [A case of hepatitis C virus-associated glomerulonephropathy presenting with MPO-ANCA-positive rapidly progressive glomerulonephritis].
    Igaki N; Nakaji M; Moriguchi R; Akiyama H; Tamada F; Goto T
    Nihon Jinzo Gakkai Shi; 2000 May; 42(4):353-8. PubMed ID: 10897595
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Successful renal transplantation in a child with ANCA-associated microscopic polyangiitis.
    Besbas N; Ozaltin F; Tinaztepe K; Güçer S; Ozen S; Bakkaloglu M; Bakkaloglu A
    Pediatr Nephrol; 2003 Jul; 18(7):696-9. PubMed ID: 12743792
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Apheresis for MPO-ANCA-associated RPGN-indications and efficacy: lessons learned from Japan nationwide survey of RPGN.
    Yamagata K; Hirayama K; Mase K; Yamaguchi N; Kobayashi M; Takahashi H; Koyama A
    J Clin Apher; 2005 Dec; 20(4):244-51. PubMed ID: 15880406
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dual anti-neutrophil cytoplasmic antibody-related pauci-immune crescentic glomerulonephritis in a patient with Sjögren's syndrome.
    Lee IH; Kim SK; Kim MK
    Rheumatol Int; 2016 Sep; 36(9):1327-34. PubMed ID: 27384449
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Poor renal outcome of antineutrophil cytoplasmic antibody negative Pauci-immune glomerulonephritis in Taiwanese.
    Hung PH; Chiu YL; Lin WC; Chiang WC; Chen YM; Lin SL; Wu KD; Tsai TJ
    J Formos Med Assoc; 2006 Oct; 105(10):804-12. PubMed ID: 17000453
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anca negative pauci-immune crescentic glomerulonephritis and mixed connective tissue disease: a case study.
    Fernandes S; Teixeira C; Falcão LP; Costa AC; Raimundo M; Silva S; Cardoso J; Almeida E
    J Bras Nefrol; 2019 Mar; 42(2):245-249. PubMed ID: 30897193
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.